基本信息
浏览量:1637
职业迁徙
个人简介
Over the past 25 years, the research group directed by Dr. Paul Ridker has been collaboratively responsible for elucidating the critical role of inflammation in the detection, prevention, and treatment of cardiovascular diseases. This work has proven the inflammation hypothesis of atherosclerosis, led to guideline endorsed use of inflammatory biomarkers in clinical practice, widely expanded the indications for statin therapy in prevention, and resulted in the development of several entirely novel therapeutics for both heart disease and cancer.
Best known for his pioneering population biology work on inflammatory biomarkers such as high-sensitivity CRP and interleukin-6 (1997), the first demonstration of the anti-inflammatory effects of statins (1998), the guideline changing JUPITER trial (2008), and ultimately through the CANTOS interleukin-1b inhibition trial (2017) and the CIRT low-dose methotrexate trial (2019), Dr. Ridker’s work has led to a fundamental shift in our understanding of atherosclerosis and to the first proof-of-principle that targeted anti-cytokine therapies can lower cardiovascular event rates in the absence of lipid lowering. Insights from his group that the magnitude of inflammation inhibition directly relates to the magnitude of clinical benefit has spawned a novel class of cardiovascular therapeutics and led to the clinical recognition that “residual inflammatory risk” is a separate and distinct entity from “residual cholesterol risk”. Moreover, in simultaneous work related to inflammation in the tumor microenvironment, Dr. Ridker demonstrated for the first time that interleukin-1b inhibition dramatically lowers lung cancer mortality (2017), work that has additionally opened an entirely novel approach to the treatment of inflammatory cancers.
Best known for his pioneering population biology work on inflammatory biomarkers such as high-sensitivity CRP and interleukin-6 (1997), the first demonstration of the anti-inflammatory effects of statins (1998), the guideline changing JUPITER trial (2008), and ultimately through the CANTOS interleukin-1b inhibition trial (2017) and the CIRT low-dose methotrexate trial (2019), Dr. Ridker’s work has led to a fundamental shift in our understanding of atherosclerosis and to the first proof-of-principle that targeted anti-cytokine therapies can lower cardiovascular event rates in the absence of lipid lowering. Insights from his group that the magnitude of inflammation inhibition directly relates to the magnitude of clinical benefit has spawned a novel class of cardiovascular therapeutics and led to the clinical recognition that “residual inflammatory risk” is a separate and distinct entity from “residual cholesterol risk”. Moreover, in simultaneous work related to inflammation in the tumor microenvironment, Dr. Ridker demonstrated for the first time that interleukin-1b inhibition dramatically lowers lung cancer mortality (2017), work that has additionally opened an entirely novel approach to the treatment of inflammatory cancers.
研究兴趣
论文共 1756 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Markus Scholz, Katrin Horn, Janne Pott,Matthias Wuttke,Andreas Kühnapfel, M. Kamal Nasr,Holger Kirsten,Yong Li,Anselm Hoppmann,Mathias Gorski,Sahar Ghasemi,Man Li,
Nature Communicationsno. 1 (2024): 1-17
Sagar B Dugani, M Vinayaga Moorthy,Olga V Demler,Chunying Li,Paul M Ridker,Robert J Glynn,Samia Mora
Clinical chemistryno. 5 (2024): 768-779
Jacob M Keaton,Zoha Kamali,Tian Xie,Ahmad Vaez, Ariel Williams, Slavina B Goleva,Alireza Ani,Evangelos Evangelou,Jacklyn N Hellwege,Loic Yengo,William J Young,Matthew Traylor,
Nature geneticspp.1-14, (2024)
Mark Petrie,Barry Borlaug, Kristine Buchholtz,Anique Ducharme, Anders Hvelplund, Carolyn Lam Su Ping, Guiomar Mendieta, Soren Ostergaard Hardt-Lindberg,Adriaan A. Voors,Paul M. Ridker
JOURNAL OF CARDIAC FAILUREno. 1 (2024): 126-126
Thomas J. Povsic,Serge Korjian,M. Cecilia Bahit,Gerald Chi, Danielle Duffy, John H. Alexander,Dragos Vinereanu, Pierluigi Tricoci, Sojaita Jenny Mears, Lawrence I. Deckelbaum,Marc Bonaca,Paul M. Ridker,
Journal of the American College of Cardiology (2024)
CIRCULATION RESEARCHno. 5 (2024): e3-e14
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGYno. 5 (2023): 414-426
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn